Stable Clonal Cell Lines for Scalable Gene Therapy
Gene therapy is revolutionizing medicine, but manufacturing viral vectors remains a bottleneck. Whether you aredeveloping Adeno-Associated Virus (AAV), lentivirus, or other delivery platforms, scalable and cost-effective gene therapies depend on stable clonal cell lines with high productivity and regulatory compliance.
After vector design and transfection, the ability to isolate, verify, and expand high-yield, monoclonal clones will determine your success in:
Deriving monoclonal pools for GMP manufacturing and regulatory approval
Maximizing vector titers
Ensuring batch-to-batch consistency
Reducing time-to-patient and cost of goods (COGS)
ADD SUBTITLE
From Millions of Clones, to the One Clone in a Million
CYTENA’s UP.SIGHT™ automates the most labour-intensive steps of cell line development in viral vector biomanufacturing. Built for biologists, it empowers you to screen better clones faster, so you can meet your program’s clinical, regulatory and financial expectations.
Discover Higher-Yield Clones Faster
Identifying top-performing clones within a transfected cell minipool is a critical step in viral vector manufacturing. Success depends on maintaining cell viability and screening a sufficient number of candidates.
With its gentle, yet fast dispensing technology, the UP.SIGHT™ dispenses a 96-well plate in just 2 minutes and achieves clonal recovery of up to 80%. It helps you save both time and resources by getting more clones to screen for titer, from fewer plates, faster.
Designed for GMP Compliance
CYTENA’s UP.SIGHT™ is engineered to support the highest standards of cleanliness, quality, and regulatory compliance in cell line development workflows.
The system fits in a safety cabinet and uses single-use, GMP-grade sterilized consumables. Monoclonality is verified through two independent imaging systems while C.STUDIO, a 21CFRpart11-compatible, clone-centric campaign management software enables the generation of regulator-ready monoclonality reports with just a few clicks.
Book a Demo
Contact the CYTENA team today for an online or on site demo!
Relevant Products
UP.SIGHT™
Purpose-built for cell line development campaigns. Optimized for single-cell dispensing into 96-well plates in just 2 minutes, UP.SIGHT™ achieves clonal recovery rates up to 80% and provides dual proof of monoclonality.
Its plate imaging enables colony outgrowth tracking and characterization assays read-out; all in a single instrument.
Clone-centric campaign management software for the UP.SIGHT that centralizes all your clone intelligence: it tracks all your clones from seeding to outgrowth, characterization, makes hit pick lists, and generates regulator-ready monoclonality reports.
.png?width=2251&height=920&name=Pfizer_(2021).png)
.png)
